Kezar Life Sciences Reports Improved Net Loss of $11.2 Million in Q3 2025

Kezar Life Sciences, Inc. reported a net loss of $11.2 million for the third quarter of 2025, a significant improvement compared to a net loss of $20.3 million in the same period of the previous year. For the nine months ending September 30, 2025, the company recorded a net loss of $41.5 million, down from $63.5 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $11.7 million for the quarter, down from $21.9 million in Q3 2024. This decline was primarily driven by a $9.3 million reduction in research and development expenses, reflecting the company's strategic decision to halt certain clinical trials.

Kezar's total operating expenses for the nine months ended September 30, 2025, were $43.9 million, compared to $69.0 million for the same period in 2024. The decrease in expenses was largely due to the termination of the PALIZADE trial and a reduction in clinical costs. General and administrative expenses also fell to $4.8 million in Q3 2025 from $5.7 million in Q3 2024, indicating a broader effort to streamline operations amid ongoing financial challenges.

In terms of financial position, Kezar reported total assets of $97.7 million as of September 30, 2025, down from $144.7 million at the end of 2024. The decrease in assets was primarily due to a reduction in cash and marketable securities, which totaled $90.2 million, down from $132.2 million at the end of the previous fiscal year. The company’s accumulated deficit reached $476 million, reflecting its ongoing investment in research and development without generating product sales.

Strategically, Kezar announced plans to explore a range of alternatives aimed at maximizing stockholder value, which includes a significant workforce reduction of approximately 70% as part of a restructuring plan. This decision is expected to incur cash expenditures of around $6 million, primarily for severance and related costs. The company has also terminated its collaboration with Everest Medicines regarding the PALIZADE trial, focusing instead on the development of its lead product candidate, zetomipzomib, for autoimmune diseases.

Looking ahead, Kezar anticipates continued operating losses as it evaluates strategic alternatives and manages its cash resources. The company believes its existing cash and marketable securities will be sufficient to fund operations for at least the next 12 months. However, it acknowledges the potential need for additional financing to support ongoing research and development efforts, as well as the uncertainty surrounding the outcomes of its strategic review process.